ArticleFrontiers in medicine2025
Burden of multiple myeloma in Asian countries from 1990 to 2021 and trend prediction for 2050: an analysis based on the Global Burden of Disease Study 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) poses a growing challenge to global public health, with regional disparities in disease burden becoming increasingly prominent. As the most populous continent, Asia is undergoing rapid demographic and socioeconomic transitions, and plays a critical role in shaping the evolutionary trajectory of the global MM burden. This study aims to assess the disease burden of multiple myeloma in Asian countries from 1990 to 2021. Methods: The data of this study were derived from the Global Burden of Disease Study 2021 database. We conducted a systematic analysis of the disease burden of MM in Asia from 1990 to 2021, covering four core dimensions: incidence, prevalence, mortality, and disability-adjusted life years (DALYs). To fully present the complexity of the disease burden, we also performed multiple analytical approaches, including trend analysis, gender-stratified analysis, regional comparative analysis, and ARIMA model prediction analysis. Results: In 2021, incident cases of MM in Asia accounted for 35.8% of the global total, prevalent cases for 34.2%, deaths for 36.3%, and DALYs for 39.7%, making Asia a key contributing region to the global MM disease burden. From 1990 to 2021, the growth rates of the above indicators in Asia were significantly higher than the global average. Moreover, ARIMA model projections indicated that Asia's MM burden would follow a "first increase, then stabilize" trajectory by 2050, with a more prominent growth magnitude and higher prediction uncertainty observed in men. This disparity may reflect a combination of metabolic, lifestyle, and genetic factors East Asia and South Asia emerged as the core regions bearing the MM burden, while Central Asia exhibited the fastest growth rate in burden. High-income regions had higher MM diagnosis rates (reducing underreporting), whereas low-income regions faced significant underestimation of the actual burden due to limited diagnostic capacity. Additionally, as socioeconomic status decreased, the average age at death of MM patients advanced. Conclusion: The study confirms that Asia has become the primary driving region for the growth of the global MM burden, and its burden pattern is influenced by significant gender disparities, regional disparities, and socioeconomic disparities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.